Organizational Integration of Acquired Biotechnology Companies into Pharmaceutical Companies: The Need for a Hybrid Approach
通过五个深度案例研究，分析了制药公司收购生物技术公司后的整合问题，提出需要采用混合整合方法，同时兼顾短期和长期目标，并在价值链不同环节以不同速度推进。
This analysis of the postacquisition integration of biotechnology companies by pharmaceutical companies addresses new issues in the pharmaceutical and biotechnology industries and includes five in-depth case studies. The guiding research question is how a biotech company is integrated into a pharmaceutical company seeking access to the biotech company's know-how, technologies, and innovative capabilities. I conclude that given the complexity and multifaceted nature of mergers and acquisitions, pharmaceutical companies need to apply a hybrid postacquisition integration approach with simultaneous short- and long-term motives/orientations and segmentation at a different pace across different value chain components.